Abstract
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Capecitabine
-
Chemotherapy, Adjuvant
-
Colorectal Neoplasms / drug therapy*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Diarrhea / chemically induced
-
Drug Administration Schedule
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives*
-
Fluorouracil / therapeutic use
-
Humans
-
Irinotecan
-
Leucovorin / administration & dosage
-
Neoadjuvant Therapy
-
Organoplatinum Compounds / administration & dosage
-
Oxaloacetates
-
Prodrugs / therapeutic use
-
Radiotherapy, Adjuvant
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antimetabolites, Antineoplastic
-
Organoplatinum Compounds
-
Oxaloacetates
-
Prodrugs
-
Deoxycytidine
-
Bevacizumab
-
Capecitabine
-
Irinotecan
-
Leucovorin
-
Fluorouracil
-
Camptothecin